Evidence map›Paper›PMID 42758304›Full record

ArticleDiabetologia2026

Unimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice.

Ananyaa Sridhar, Ethan S Palmer, Sarah L Craig, Neil Tanday, Finbarr P M O'Harte, Nigel Irwin

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ananyaa SridharCentre for Diabetes, School of Biomedical Sciences, Ulster University, Coleraine, UK.
Ethan S PalmerCentre for Diabetes, School of Biomedical Sciences, Ulster University, Coleraine, UK.
Sarah L CraigCentre for Diabetes, School of Biomedical Sciences, Ulster University, Coleraine, UK.
Neil TandayCentre for Diabetes, School of Biomedical Sciences, Ulster University, Coleraine, UK.
Finbarr P M O'HarteCentre for Diabetes, School of Biomedical Sciences, Ulster University, Coleraine, UK.
Nigel IrwinCentre for Diabetes, School of Biomedical Sciences, Ulster University, Coleraine, UK. n.irwin@ulster.ac.uk.

Funding

Invest Northern Ireland Proof-of-Concept grant (PoC 825)Northern Ireland Department for Education PhD studentship
6 · The paper itself

Abstract

aims/hypothesisThe aim of this study was to determine the applicability of dual activation of glucagon-like peptide-1 (GLP-1) and apelin (APJ) receptors as a next-generation therapeutic option for obesity and diabetes.

methodsA fully characterised unimolecular dual GLP-1/APJ receptor agonist, namely exendin-linker-apelin (ELA), as well as its acylated long-acting equivalent, ELA-Lys

resultsELA, and particularly ELA-Lys CONCLUSIONS/

interpretationChronic administration of ELA, and especially ELA-Lys

Indexed as

ApelinAPJ receptorBody weightGLP-1GluconeogenesisMetabolism

Identifiers

PMID42758304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.